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An 8-year-old neutered Beagle dog was presented with polyuria and polydipsia. Routine 
clinicopathologic testing showed a significant lymphocytosis and proteinuria. Lymphocytes were of 
small to intermediate in size with a mature morphology. Infectious disease screening was negative. 
PCR for antigen receptor gene rearrangements (PARR) showed a clonal T-cell receptor (TCR) 
rearrangement consistent with T-cell chronic lymphocytic leukemia (CLL). Bone marrow cytology 
showed <30% lymphocytes, while the proportion in splenic fine-needle aspirate cytology was 
considered increased. The dog was initially monitored but started on prednisolone and chlorambucil 
therapy two months later due to worsening clinical signs and progressive lymphocytosis. After an 
additional two weeks, the dog developed multifocal spinal pain and single-node lymphadenomegaly. 
Cytology of the lymph node showed a monomorphic population of large lymphoblasts consistent 
with lymphoma. Cytology of a cerebrospinal fluid sample also showed large lymphoblasts. PARR at 
both sites showed a clonal TCR rearrangement of the same molecular size as in the initial leukemic 
cells. The dog was diagnosed with a transformation of the CLL to Richter syndrome with involvement 
of the central nervous system (CNS). Therapy was started with L-asparaginase and an increased dose 
of prednisolone; however, the dog was euthanized due to progressive clinical signs. To our 
knowledge, this is the first report of canine Richter syndrome (RS) with direct involvement of the 
CNS.  









An 8-year-old, 11.7kg female neutered Beagle was initially referred to the University of Glasgow 
Small Animal Hospital, with a 6-week history of polyuria and polydipsia (PUPD). A peripheral 
lymphocytosis (32.9 x109/l) had been detected by the referring veterinarian. No medications had 
been administered prior to referral.  
The initial clinical examination was unremarkable, with no evidence of peripheral 
lymphadenomegaly, a normal body condition score, and normal temperature. The dog was reported 
to be well aside from the PUPD. Results of a CBC (Advia 120, Siemens, Frimley, UK) showed a mild 
lymphocytosis (8.72 x109/L), but the dog was otherwise normal (Table 1). A blood smear 
examination revealed a monomorphic population of lymphocytes, which were small to intermediate 
in size with clumped chromatin and scant to moderate amounts of pale cytoplasm, which often 
contained a few fine magenta granules (Figure 1).  A biochemistry panel showed mild 
hypoalbuminemia (26 g/l) and hypophosphatemia (0.92 mmol/l) (Table 2). Electrolytes, including 
calcium, were within reference intervals (WRI). The urinalysis showed an inactive sediment, but an 
increased urine protein:creatinine ratio (UPC) of 4.27 with a urine specific gravity (USG) of 1.002. The 
urine culture was negative. An abdominal ultrasound revealed no abnormalities, nor did the thoracic 
computed tomography (CT). A further investigation into the cause of the lymphocytosis was 
performed with point-of-care serology for Anaplasma Phagocytophilium, Anaplasma Platys, Borrelia 
Burgdorferi, Ehrlichia canis, Ehrlichia ewingii plus a Dirofilaria antigen (SNAP 4Dx Plus, IDEXX, UK) 
that were all negative.  
Clonality of the lymphocytosis was evaluated by PCR for antigen receptor gene rearrangement 
(PARR), performed on the peripheral blood as previously described1. A clonal TCR rearrangement 
was detected; however, there was evidence of DNA degradation within the sample, and this result 
was regarded with caution.  As such, the dog returned a week later for a repeat hematology panel, 
which showed a more marked lymphocytosis of 30 x109/L, and PARR was repeated at this time. The 
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second analysis demonstrated a clonal TCR rearrangement of the same molecular size (66 bp; Figure 
2A). Amplification with immunoglobulin primer sets yielded only small polyclonal distributions 
(presumed to be a residual normal B-cell population). Based on these findings, a diagnosis of T-cell 
chronic lymphocytic leukemia (CLL) with concurrent proteinuria was made.   
To help determine the source of the circulating leukemic cells, fine-needle aspirates (FNAs) were 
obtained from the rib bone marrow and spleen. Cytology of the rib bone marrow showed an M:E 
ratio of 2.1:1 with all cell lines present and intact progression of all lineages. Lymphoid cells made up 
17% of the nucleated cell count, with the majority being small to intermediate in size with a mature 
morphology. Splenic cytology showed mainly small- to intermediate-sized, mature lymphoid cells, 
with occasional lymphoblasts and plasma cells. In dogs, CLL is considered to be primarily of bone 
marrow origin when the marrow contains >30% small mature-appearing lymphocytes. Given the 
comparatively lower lymphocyte percentage found within the marrow sample, in this case, and the 
predominance of small lymphocytes within the spleen, the spleen was considered the most likely 
source of the peripheral leukemia.  This hypothesis is consistent with the presumed CLL phenotype: 
while B-cell CLL is usually of marrow origin, T-cell CLL is commonly thought to be of splenic origin 2,3.  
Supportive therapy for the proteinuria was initiated with benazepril (0.5 mg/kg SID), plus clopidogrel 
(3 mg/kg SID) as thromboprophylaxis. No specific CLL therapy was started at this stage, as the dog 
was clinically well. At subsequent revisits, the dog remained clinically stable, with a non-changing 
lymphocytosis that lasted until two months after the initial visit. At that point the PUPD worsened, 
and the lymphocytosis was persistently increased (44 x109/L). Clinical examination remained normal, 
with no detectable lymphadenomegaly. Biochemistry and electrolytes remained WRI. The 
proteinuria had initially improved with benazepril but increased again (UPC 4.43). The decision was 
made to start therapy for CLL using a prednisolone-chlorambucil protocol therapy (chlorambucil 4 
mg/m2/24h prednisolone 40 mg/m2/24h for the first 7 days, reduced by half thereafter). Two weeks 
later, the owner reported that the dog was more lethargic, and was showing stiffness, an 
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intermittent right forelimb lameness, and a stilted gait. Clinical examination found thoracic and 
lumbosacral spinal pain, plus an enlargement of the right retropharyngeal lymph node (RPLN). The 
rest of a full neurologic exam was unremarkable, and the orthopedic exam identified no focus of 
pain on the right forelimb. CT of the neck and lumbar spine were unremarkable. Hematology 
showed a reduction in the lymphocytosis to 11.4x109/L, but a leukemic blood picture with small to 
intermediate lymphocytes was still apparent (Table 1). FNAs were taken for cytology from the RPLN, 
and the dog was discharged for the weekend with analgesia (paracetamol 10 mg/kg/12h) pending 
results.  RPLN cytology demonstrated a monomorphic population of intermediate to large 
lymphoblasts admixed with lower numbers of small lymphocytes. The neoplastic cells had a scant to 
moderate band of deeply basophilic cytoplasm, with a few fine pink granules and small perinuclear 
clearing occasionally seen. The nucleus contained finely stippled chromatin with multiple indistinct 
nucleoli. An occasional hand-mirror morphology was observed, and several mitotic figures were 
present (Figure 3).  
Given these results, the dog returned to the hospital two days later for repeat staging of her 
lymphoid neoplasia. Her owners reported ongoing spinal pain and worsening lethargy. Repeat 
hematology (Table 1) showed the lymphocyte count had normalized, and occasional large 
lymphoblasts were now present in circulation (Figure 4). The biochemistry panel indicated 
persistence of the mild hypoalbuminemia, and the urinalysis showed the proteinuria had worsened 
markedly (UPC 18.3). On abdominal ultrasound, the liver was enlarged and diffusely hyperechoic 
with rounded margins; these changes were consistent with chronic corticosteroid administration. 
There were no changes to the spleen or the abdominal lymph nodes. No overt abnormalities were 
observed on splenic cytology, although the sample size was small. Thoracic radiographs showed no 
concerns for intrathoracic lymphadenomegaly.  Magnetic resonance imaging (MRI) of the whole 
spine in T1, T2, and STIR sequences showed no structural changes to explain the spinal pain; 
however, a contrast agent was not used due to concerns regarding the potential for pre-existing 
renal disease.  
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Cisternal cerebrospinal fluid (CSF) analysis revealed an increased protein concentration (1200 mg/l), 
occasional red cells (15/ul), and a nucleated cell count of 895/ul. Cytocentrifuged preparations 
showed that the majority of cells were a monomorphic population of large lymphoblasts. These cells 
had finely stippled chromatin, multiple nucleoli, and basophilic cytoplasm, often with a perinuclear 
clearing. Frequent mitotic figures were observed. Rare small mature lymphocytes and plasma cells 
were also present (Figure 5). Morphologically, the neoplastic population in the lymph node and CSF 
appeared highly similar. PARR was performed on both and demonstrated a clonal TCR 
rearrangement of the same molecular size (66 bp), like that seen previously in the peripheral blood 
(Figure 2B and 2C). This was interpreted as consistent with Richter syndrome (RS), a transformation 
of the previous CLL into a clonally related high-grade lymphoma in both the RPLN and CNS.  
Therapy was started with L-asparaginase (10,000 IU/m2 s/c), and the prednisolone was increased 
back to 1.5 mg/kg/24h, with a plan to continue with a lomustine- or a cytosine arabinoside-based 
protocol after that. Chlorambucil was discontinued. Analgesia was increased with the addition of 
tramadol (2 mg/kg/8h) and gabapentin (10 mg/kg/8h). The dog’s comfort improved markedly, but 
she remained quiet, and developed tonic-clonic seizures within 24 h. These were successfully 
managed with the addition of phenobarbitone (1 mg/kg/12h). At re-examination, three days after 
the change in chemotherapy, the dog remained quiet and comfortable and had had no further 
seizures and maintained a good appetite. The hematology results showed the development of a mild 
poorly regenerative anemia (HCT 31%), lymphopenia (0.8 x109/L), and mature neutrophilia (18 
x109/l). The platelet count was also mildly reduced (132 x1012/L). The owners elected to continue 
palliative care only and discontinue the chemotherapy. The dog was euthanized two days later due 
to worsening lethargy. The survival time of this dog was 111 days from the first detection of the 
lymphocytosis by the referring veterinarian, and 12 days from the detection of the enlarged lymph 





The finding of a clonal TCR rearrangement of the same molecular size in the large lymphoblasts of 
the CSF and RPLN as in the initial peripheral intermediate-sized leukemic cells was consistent with a 
malignant transformation of the initial CLL. This transformation of CLL into high-grade lymphoma is 
known as RS in humans. Canine RS has been rarely reported, with only 10 cases previously 
documented in the literature4,5. While neurologic signs were described at the point of 
transformation in some of those cases, the development of confirmed CNS lymphoma as part of RS 
has never been reported in dogs.  
In human medicine, RS occurs in 3.3 to 10.6% of patients with CLL6,7. Most commonly, the 
transformed neoplastic population arises from lymph nodes or bone marrow and then spreads to 
other organs. Asymmetric lymphadenomegaly, or lymphadenomegaly at a single site, as seen in this 
case, is common6. The mechanisms by which CLL transforms into RS are poorly understood, but viral 
infections such as Epstein-Barr virus, and chromosomal abnormalities such as Trisomy 12 have been 
implicated in some patients 6,8,9. The development of a second new hematopoietic neoplasm of 
different lineage in human patients with CLL can also occur and has been reported once in a dog6,10. 
In human medicine, cases of RS with clonally-unrelated de novo lymphomas have a better prognosis 
than those with the classic clonally-related lymphomas, leading to suggestions that the former 
should not be considered a true Richter transformation6.   
Development of CNS lymphoma as part of human RS is very rare but has been reported both 
alongside nodal enlargement as the most common variant and as isolated RS in the CNS7,9,11. There 
are, however, several different mechanisms described by which human CLL patients could develop 
neurologic signs in addition to developing CNS RS. In one study of CLL patients that developed 
neurologic signs, only 19% of the cases were caused by direct neoplastic involvement of the CNS, 
with the majority being due to other etiologies such as infections or autoimmune/inflammatory 
conditions7. In those cases, where there is direct CNS involvement, illnesses could have been due to 
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extramedullary CLL, where the CSF analyses revealed the same population of small/intermediate 
lymphocytes as in the blood samples, or as CNS RS, where the population of neoplastic lymphocytes 
is different between those in the CNS and those in the blood. In that same study, these two forms 
were seen in roughly equal proportions, of around 10% of the cases7. CNS RS can, in some cases, 
only affect the leptomeninges, and in other cases, present as a mass lesion affecting the brain 
parenchyma7,11. There was also one case with suspected spinal cord involvement12. It is also 
noteworthy that up to 70% of human CLL patients show asymptomatic CNS CLL involvement7. While 
some human CNS RS cases can be confirmed on CSF analysis alone, the majority require a tissue 
biopsy for diagnosis7. In the dog of this study, we diagnosed CNS RS based on the presence of a 
clonal population of large lymphoblasts in the CSF. These lymphoblasts showed the same T-cell 
clonal rearrangement as those seen in the peripheral lymph node. Alternative explanations for the 
presence of the lymphocytes in the CSF sample could have included contamination of the sample by 
peripheral blood and the introduction of peripheral leukemic cells. We feel these are unlikely for a 
number of reasons. First, only occasional erythrocytes were seen in the sample, suggesting minimal 
blood contamination. Secondly, on the cytologic exam, the lymphoid cells were large lymphoblasts 
of the same morphology of those seen in the RPLN and not small to intermediate CLL lymphocytes, 
as had been seen in the peripheral blood smears. Thirdly, the dog was no longer leukemic by the 
time the CSF sample was taken, so blood contamination should not have introduced a significant 
number of peripheral lymphocytes into the CSF sample. Thus, we feel that the presence of the 
lymphocytes in the CNS corresponds with CNS RS in this dog, and not simply with blood 
contamination or extramedullary CLL. Interestingly, on MRI,  no changes suspicious for CNS 
lymphoma were seen. While CNS RS has not been reported in dogs previously, canine CNS 
lymphoma is also only rarely seen, and as such, limited cases have been described in the literature 
13–17. CNS lymphoma has been reported in dogs both as a primary tumor and as part of the 
progression of multicentric lymphoma13,14,17. Although most reported canine CNS lymphoma cases 
had MRI changes on plain T2 sequences, all have been described as highly contrast enhancing15,16. A 
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limitation in this case report is that contrast was not used because of concerns about the dog’s renal 
function based on the pre-existing persistent proteinuria. Thus, there could have been undetected 
contrast-enhancing changes in the spine or leptomeninges. Additionally, the brain was not imaged as 
the neurologic signs were only localized to the spinal cord at the time of MRI. Since the dog 
presented with seizures 24 h later, it is also possible that an undetected brain lesion was present. 
Notably, however, in human medicine, a significant proportion of human CLL cases with CNS 
involvement do not have changes on MRI 7.  
Interestingly, in a previously reported case series of canine RS, all dogs had a decrease in lymphocyte 
counts at the point of transformation with two developing lymphopenia5. Additionally, six of the 
eight cases began to show lymphoblasts in circulation at the same timepoint. The dog reported here 
showed both of these changes, with a sudden lymphocyte count normalization around the time that 
the lymphadenomegaly developed, which then progressed to a lymphopenia with occasional 
circulating lymphoblasts. Changes to peripheral CLL lymphocyte counts have not been reported in 
humans with RS, while only occasional cases have shown circulating lymphoblasts, 6 which suggests 
that it is prudent to closely monitor canine CLL cases with a sudden drop in lymphocyte counts, as 
this could be an early sign of RS. 
In this case, PARR indicated both the initial CLL and subsequent RS were of T-cell type. Of the 
previously reported canine RS cases, two were not immunophenotyped, while two were T-cell CLL 
and six B-cell CLL 4,5. In human medicine, RS occurs in 2-20% of B-cell CLL cases, with T-cell CLL 
transformation into lymphoma being only rarely described6. Unlike in dogs, however, B-cell CLL is 
the most common immunophenotype in people, so it is perhaps unsurprising that B-cell RS is also 
the most common type. Canine CNS lymphoma has been described as both T- and B-cell 
immunophenotypes; however, due to the rare nature of the disease, it is still unclear whether one 
immunophenotype is more common than the other13. Classically, T-cell CLL is considered to have a 
better prognosis in dogs compared with B-cell CLL; however, a recent study showed that a 
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proportion of dogs with ‘atypical’ T-cell CLL, based on flow cytometric immunophenotyping, had a 
very poor prognosis3,18. Immunophenotyping was not performed in this case; instead, the diagnosis 
was made by the detection of clonality using PARR. It is possible that flow cytometry could have 
provided further prognostic information. This dog survived only 111 days from the initial CLL 
diagnosis, and 12 days from RS detection with the symptoms of RS being the deciding factors for 
euthanasia. In the previous canine case series, the median survival was similarly poor, at 41 days 
from the development of RS5. In human medicine, the prognosis for RS is likewise considered poor, 
with a median survival of less than 6 months6,8. The limited number of CNS RS cases also followed 
this pattern, and in one study, 80% of cases with CNS RS had died within 12 months of diagnosis7. 
There is no consensus on the best therapeutic approach, with various combinations of 
chemotherapy and immunotherapy attempted; however, the response rates were also poor, ranging 
from 5-43% 6,8. Local irradiation has also been used for cases with brain involvement 7,9,11. This dog 
did not show significant improvement with the initial therapy of L-asparaginase and an increased 
prednisolone dose; however, further chemotherapy was not pursued. No consensus in veterinary 
medicine has been proposed for CNS lymphoma therapy, with chemotherapeutic agents, such as 
cytosine arabinoside, methotrexate, and lomustine, plus local irradiation and surgery for focal 
lesions, all being reported 13. However, the prognosis for CNS RS in dogs should be considered 
guarded based on the dog of this study and the previously reported cases of canine RS and canine 
CNS lymphoma.  
In conclusion, this report outlines a case of canine T-cell CLL transforming to RS, presenting with 
both single-node lymphadenomegaly and multifocal spinal pain. CNS involvement was shown by the 
presence of significant numbers of large lymphoblasts on CSF cytology that had a clonal TCR 
rearrangement of the same molecular size as in the cells in the lymph node and those in the blood at 
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Table 1: Serial Hematologic data from a dog with T-cell chronic lymphocytic leukemia progressing to 
Richter syndrome.  
  unit RI Day 1 Day 15 Day 79 Day 95 Day 98 Day 105 
RBC  x109/l 5.5-8.5 6.61 8.05 7.95 7.45 6.19 4.7 
HCT  % 37-55 47.6 58.4 55.1 49.3 40.5 31 
Hb  g/dl 12-18 15.1 18.3 17.9 17 13.5 11 
MCV  fl 60-77 72 72.6 69.4 66.2 65.4 65.9 
MCHC  g/dl 32-36 31.8 31.3 32.5 34.4 33.3 35 
WBC  x109/l 6-12 16.1 37.5 50.6 18.9 11.7 20.6 
band neutrophils  x109/l   0 0 0 0 0 0.4 
neutrophils  x109/l 3-11.8 6.8 6.4 5.1 6.8 9.3 18.2 
lymphocytes x109/l 1-4.8 8.7 30 44 11.4 1.8 0.8 
monocytes  x109/l 0.15-1.35 0.3 0.8 1 0.8 0.6 0 
eosinophils  x109/l 0.1-1.25 0.3 0.4 0.5 0 0 1.2 
basophils  x109/l 0 0 0 0 0 0 0 
PLT  x109/l 200-500 380 420 433 403 346 132 
Reference intervals (RIs) are from the laboratory at the Veterinary Diagnostic Services of the University of Glasgow. PCV, 






Table 2: Biochemical data from from a dog with T-cell chronic lymphocytic leukemia progressing to 
Richter syndrome on the initial presentation.  
  unit RI Day 1 
total protein g/l 50-78 59 
albumin g/l 29-36 26 
globulin g/l 28-42 33 
sodium mmol/l 136-159 144.1 
potassium mmol/l 3.4-5.8 4 
chloride mmol/l 95-115 112.6 
calcium mmol/l 2.34-3 2.54 
phosphate mmol/l 1.29-2.9 0.92 
urea mmol/l 2.5-8.5 2.7 
creatinine umol/l 45-155 66 
total bilirubin umol/l <10 2 
ALT U/l <90 19 
ALKP U/l <230 62 
Reference intervals (RIs) are from the laboratory at the Veterinary Diagnostic Services of the University of 






Figure 1: A photomicrograph of a blood smear from a dog with T-cell chronic lymphocytic leukemia 
progressing to Richter syndrome. A lymphocytosis was present that consisted of predominantly 
small- to intermediate-sized lymphocytes. A few fine magenta cytoplasmic granules were seen in 




Figure 2: Electropherograms of PCR for antigen receptor gene rearrangements from a dog with T-cell 
chronic lymphocytic leukemia progressing to Richter syndrome. A, peripheral blood, B, the 
retropharyngeal lymph node, and C, cerebrospinal fluid. Products were amplified using a T-cell 
receptor gamma primer set, as previously described (Waugh et al 2016). Size markers are in red 
(GeneScan 500 ROX, Fisher Scientific, Loughborough). A clonal peak (blue) of approximately 66 base 
pairs was amplified from all three samples. The lower amplitude of the peak in sample C (CSF) 




Figure 3: Photomicrographs of a fine-needle aspirate from the right retropharyngeal lymph node of a 
dog with T-cell chronic lymphocytic leukemia progressing to Richter syndrome. A predominance of 
large lymphoblasts can be seen. A few small lymphocytes are also present (black arrow). Occasional 
cells show a hand-mirror morphology (white arrow), and occasional mitotic figures were observed 




Figure 4: A photomicrograph of a blood smear from a dog with T-cell chronic lymphocytic leukemia 
progressing to Richter syndrome. Lymphocyte numbers were within reference intervals and were 
predominantly small, with occasional large lymphoblasts observed (arrow). ×400 objective, May 




Figure 5: A photomicrograph of cerebrospinal fluid (cisternal) from a dog with T-cell chronic 
lymphocytic leukemia progressing to Richter syndrome. A Predominance of large lymphoblasts are 
seen, often showing perinuclear clearing. Rare small lymphocytes (black arrow) and several mitotic 
figures (white arrow) were also noted. ×400 objective, May Grünwald Giemsa stain 
 
 
 
